Open Nav

Please submit your session questions in advance at

CEL-SCI Corporation

  • Geert Kersten, CEL-SCI Corporation

CEL-SCI is a pioneer in cancer immunotherapy. We believe that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Consequently, in its Phase 3 clinical study CEL-SCI is treating patients who are newly diagnosed with advanced primary head and neck cancer with Multikine BEFORE they receive surgery, radiation and/or chemotherapy. The Phase 3 trial is the largest ever in head and neck cancer with 928 patients enrolled. With the last patient enrolled in the study in September 2016, final data read-out based on 298 events is expected in the near future. Multikine has received Orphan Drug designation from the FDA. Advanced primary head and neck cancer represents an unmet medical need with the last FDA approval about 60 years ago.

CEL-SCI's LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the NIH. The Company has operations in Vienna, VA, and Baltimore, MD.

  • Date:Monday, February 11
  • Time:2:00 PM - 2:15 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23322
  • Goal for Presentation:Expand our exposure to new investors and representatives in the Biotech/Pharmaceutical Industry
  • Company
  • Company HQ City:Vienna
  • Company HQ State:Virginia
  • Company HQ Country:United States
  • Market Cap:90 million
  • Ticker:CVM
  • Exchange:NYSE American
  • CEO/Top Company Official:Geert Kersten
  • Year Founded:1983
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Multikine (Leucocyte Interleukin, Injection)
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
  • Additional Information/Comments:CEL-SCI's Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the Phase 3 study's protocol, newly diagnosed patients with advanced primary squamous cell carcinoma are treated with the Multikine treatment regimen for 3 weeks prior to the Standard of Care (SOC) which involves surgery, chemotherapy and/or radiation. Multikine is designed to help the immune system "see" the tumor at a time when the immune system is still relatively intact and thereby better able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body's immune system prior to SOC.
Geert Kersten
CEL-SCI Corporation